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The letter of Schmucker et al. is much appreciated.
It reflects their careful reading of our article. They
address one of the major issues in medicine: what
constitutes the evidence base of medicine, and when
should doctors start treating patients? We would like to
reflect on this issue, and address some of the points
raised by Schmucker et al.
The case of bevacizumab has strong similarities with
the discovery of insulin. In 1922, Leonard Thompson
was the first patient who received insulin [1]. The effects
were spectacular. No one had any reasonable doubt that
this was due to insulin. Without any randomised controlled
trial, insulin has changed the life of many patients with
diabetes.
The authors state that “ It is common knowledge that
due to a missing control group no conclusions on
efficacy can be drawn from case series (refers to
before-and-after studies in the review by Schouten et
al.).” We, and especially one of us who is an associate
professor in clinical epidemiology (JS) are well aware of
this common knowledge. However, when the issue of
whether the observed change in visual acuity in the
before-and-after studies is caused by bevacizumab is
addressed, prior knowledge should be taken into account.
Schmucker et al. will recognise this as a “Bayesian
approach”.
This prior knowledge constitutes the results from other
studies like those on:
– the reported increase of VEGF in AMD,
– the inhibitory effect of VEGF on the formation of new
vessels,
– the inhibitory effect of VEGFs on an occurrence of
leakage in these vessels,
– basic science on the structure of bevacizumab and its
blocking effect of VEGFs,
– the levels of free VEGF in the eye after intravitreal
administration of bevacizumab,
– its positive effect in other diseases with the same
pathogenesis of neovascularisation such as cancer,
– the results of an RCT on the effect on visual acuity of
an almost similar molecule with the same property of
blocking VEGFs (ranibizumab).
In addition to the knowledge from other studies,
experience from ophthalmologists who treat patients with
AMD should be taken into account. One may not take this
as solid scientific evidence, but it contributes to the prior
view on the effect of bevacizumab. The case of bevacizumab
is similar to the case of insulin when one has seen the
disappearance of neovascularisation, e.g. in the case of
rubeosis of the iris or the disappearance of macular fluid after
the injection of bevacizumab.
The issues of methodological shortcomings as addressed
by Schmucker et al. are much appreciated, but as good
clinicians we need to decide whether the observed change in
visual acuity is due to the drug or bother about possible
methodological shortcomings. The prior odds are against an
explanation by methodological shortcomings. Moreover, we
have addressed this issue in a formal way by subgroup
analysis based on quality characteristics of the studies. No
The authors had no commercial or proprietary interest.
J. S. A. G. Schouten (*) : E. C. La Heij :C. A. B. Webers :
I. J. Lundqvist : F. Hendrikse
Department of Ophthalmology, Maastricht University Hospital,
PO box 5800, 6202 AZ Maastricht, The Netherlands
e-mail: Jschou@soog.azm.nl
Graefes Arch Clin Exp Ophthalmol (2010) 248:453–454
DOI 10.1007/s00417-009-1244-x
large differences between subgroups were observed. Based on
our experience as ophthalmologists, the major methodological
issue that may cause a bias is, to our opinion, the way the
assessment of the visual acuity was conducted. This was
mentioned in our review.
There is always room for doubt, but one has to decide
whether there is any reasonable doubt. Ultimately, the
question should be answeredas to whether patients with
AMD should be treated with bevacizumab or not. Or
should we decide that the observed change in visual acuity
is due to methodological shortcomings? Given our current
knowledge, in its broadest sense, can we withhold this
treatment from patients? Should we wait for a randomised
placebo controlled trial?
The definition of evidence-based medicine is: “the
judicious use of the best current evidence in making
decisions about the care of the individual patient.
Evidence-based medicine (EBM) is a means to integrate
clinical expertise with the best available research evidence and
patient values.” The most important word is “judicious”;, it
also reflects the most difficult part.
Safety of a drug is another issue raised by Schmucker
et al. First and foremost, the safety of a drug can hardly, if
ever be proved. Observed, presumed adverse events can be
reported, and the incidence be calculated. For that reason,
we did not conclude whether bevacizumab was safe, as is
often stated in other studies, but confined ourselves to the
incidence of adverse events.
Cases and case series of observed presumed adverse
events show the possible adverse events; their risk can not
be calculated. The incidence we calculated was based on
the reported adverse events in the cited articles that were
used in the systematic review. We deliberately spoke about
reported adverse events.
We did not limit ourselves to these studies. We compared
them with the calculated incidence from the data of the
International Intravitreal Bevacizumab Safety Survey [2].
This registration may not have complete data. For that
reason, we also compared the results with the data from a
prospective follow-up study with careful follow-up of 1,265
consecutive patients with various diagnoses, including
exudative AMD, who received 4,303 intravitreal injections
of bevacizumab [3]. The follow-up to discover adverse
events was thorough. As stated by the authors: “Monitored
systemic conditions included myocardial infarction, stroke,
systemic hypertension, thromboembolic diseases and death.
Blood pressure was measured prior to bevacizumab injection
and at 2 weeks following each injection. Other systemic
conditions were assessed by a thorough review of systems. All
patients were contacted in December 2006 and January 2007,
and asked to return for a check-up. If the patients were unable
to attend, a telephone interview was conducted to assess for
possible systemic complications.” The reported incidences
were mentioned explicitly in our article.
Compared with these studies, the observed adverse
events and the incidences in the studies included in the
systematic review were not that different.
Again, the prior odds of developing systemic adverse
events could be considerable if taking into account the adverse
events that occur when bevacizumab is given intravenously.
However, the dosage given in the case of cancer ranges from 5
to 15 mg/kg. The dosage for an intravitreal injection is usually
1.25 mg. This is about 1/300 to 1/1000 the dose given in
patients with cancer. Moreover, the dose is given in a
compartment (the eye) and not intravenously. The much
lower dose and injection in a compartment make it a priori less
likely that dose-dependent systemic adverse events as seen in
cancer patients will occur to the same extent as after
intravenous injections.
Since bevacizumab is used frequently over the whole
world, and is used in many studies in humans, we have
much experience with intravitreous bevacizumab and we
know much about its adverse events.
Safety can never be guaranteed, but the adverse events
and their incidence should be weighed against its benefit. In
the case of AMD, the balance is in favour of giving
bevacizumab.
We agree with Schmucker et al. that the longterm safety
of bevacizumab is not yet known. But there is only one
way to discover this, and that is by giving bevacizumab.
Post-marketing surveillance is essential.
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